A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

Trial Profile

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs PLX 73086 (Primary)
  • Indications Giant cell tumour of tendon sheath; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 19 Mar 2018 Status changed from active, no longer recruiting to discontinued.
    • 15 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
    • 01 Aug 2017 Planned End Date changed from 1 Oct 2019 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top